Echo Therapeutics Announces Positive Clinical Trial Results of Symphony® tCGM System
Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced positive results from its clinical trial of the Symphony tCGM System in elective cardiac surgery patients. This study is the first of two studies Echo is conducting in critically ill patients, with results from the second study expected later this quarter.
Data from this study demonstrate that Symphony successfully and continuously monitored glucose levels in the cardiothoracic surgical intensive care unit at Tufts Medical Center in Boston, Massachusetts. Data analysis demonstrated that Symphony read glucose levels accurately, with a mean absolute relative difference (MARD), or error rate of 12.3%.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.